A

Alexion

Global biopharmaceuticals focusing on rare diseases

Executive Director - Head of US Rare Endocrinology and Rare Tumors

Biology & BiotechPosted on Nov 10
Full-timeBoston, MA, USA

About the Job

Requirements

  • An M.D., PharmD, Ph.D., or equivalent advanced scientific or clinical degree is required.
  • At least 12 years of biopharmaceutical industry experience, including significant Medical Affairs leadership responsibility, is required.
  • At least 10 years of experience leading and managing teams, including Medical Affairs organizations, is required.
  • Demonstrated experience developing and implementing medical strategy across multiple assets, indications, or product lifecycle stages, including marketed and pipeline assets, is required.
  • Rare disease experience is required.
  • Demonstrated ability to influence senior leaders, external experts, and cross-functional partners while advancing medical strategies that improve patient care and outcomes is required.
  • Demonstrated ability to use digital, data, and AI-enabled capabilities to improve organizational effectiveness, accelerate decision-making, and enhance Medical Affairs impact is required.

Responsibilities

  • Advance understanding of the US Rare Endocrinology and Rare Tumors medical and treatment landscape, including evolving standards of care, unmet patient needs, evidence gaps, external expert perspectives, and emerging scientific developments, to inform US Medical Affairs strategies aligned with Global Medical Affairs priorities.
  • Lead the design and execution of strategy and tactical plans for assigned tumors, aligned with Global strategy and US priorities.
  • Serve as the senior US medical leader for the therapeutic area, representing it in US leadership forums, global governance discussions, and cross-functional portfolio planning.
  • Lead and develop a high-performing Medical Affairs team, including Medical Directors, Regional MSL Directors, Medical Science Liaisons, and other therapeutic-area team members as applicable.
  • Define portfolio priorities, resource needs, and budget planning across the tumor areas, ensuring trade-off decisions are linked to patient impact, evidence gaps, launch priorities, and business-critical achievements.
  • Partner with Commercial, Market Access, HEOR, Regulatory, Clinical Development, Medical Operations, Patient Advocacy, and Global Medical Affairs to ensure cross-functional alignment and combined planning.
  • Provide leadership for launch readiness, lifecycle management, and evidence-generation activities, including identifying data gaps and prioritizing real-world evidence, investigator-sponsored research, and company-sponsored research opportunities.
  • Lead monthly and quarterly reviews of US Medical Affairs activities, including field medical performance, medical insights, evidence-generation progress, and tactical-plan execution.
  • Ensure timely, high-quality publication planning and medical communications supporting Global and US Medical Affairs strategy.
  • Drive scientific exchange strategy, advisory boards, congress engagement, thought-leader development, and external expert engagement across relevant rare-disease communities.
  • Collaborate with HEOR and other partners to translate medical insights and evidence gaps into strategic actions that support improved patient care and outcomes.
  • Partner with Global Medical Education and internal scientific-training teams to localize and develop medical content for field medical scientific exchange and cross-functional education.
  • Ensure medically accurate, scientifically balanced, compliant content-review processes for promotional and non-promotional materials, as appropriate for the role.
  • Drive strategic adoption of AI and digital innovation within the Rare Endocrinology and Rare Tumors Medical Affairs organization.
  • Identify training and development needs with key partners and ensure implementation of medical training programs for field medical teams and other team members as appropriate.

Desired Qualifications

  • Rare disease experience in endocrinology, oncology, rare tumors, or a related therapeutic area is strongly preferred.
  • Product lifecycle management, launch readiness, and indication-expansion experience is preferred.
  • Experience in early- and late-stage clinical development, evidence generation, real-world evidence, and/or investigator-sponsored research is preferred.
  • Experience representing a therapeutic area in senior leadership forums, global governance discussions, major congresses, professional societies, advocacy engagements, or external scientific forums is preferred.
  • Experience leading Medical Affairs strategy in a rare-disease portfolio with small patient populations, complex diagnostic pathways, and specialized centers of excellence is preferred.

About the Company

Alexion

Global biopharmaceuticals focusing on rare diseases

Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Boston, MA
Founded
1992

Recently Posted Jobs

Explore more opportunities at Alexion

See more jobs